【研究室主要论文】
?Fujiwara N, Matsushita Y, Tempaku M, Tachi Y, Kimura G, Izuoka K, Hayata Y, Kawamura S, Eguchi A, Nakatsuka T, Sato M, Ono A, Murakami E, Tsuge M, Oka S, Hayashi A, Hirokawa Y, Watanabe M, Parikh ND, Singal AG, Marrero JA, Hoshida Y, Mizuno S, Tateishi R, Koike K, Fujishiro M, Nakagawa H. AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2025. doi: 10.1097/HEP.0000000000001360.
?Nagaoki Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, Murakami E, Kawaoka T, Miki D, Aikata H, Hayes CN, Tsuge M, Oka S. Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma. Therap Adv Gastroenterol. 18:17562848251324094, 2025.
?Kosaka M, Fujino H, Tsuge M, Yamaoka K, Fujii Y, Uchikawa S, Ono A, Murakami E, Kawaoka T, Miki D, Hayes CN, Kashiyama S, Mokuda S, Yamazaki S, Oka S. Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B. J Gastroenterol. 60(4): 469-478, 2025.
?Bao H, Murakami S, Tsuge M, Uchida T, Uchikawa S, Fujino H, Ono A, Murakami E, Kawaoka T, Miki D, Hayes CN, Oka S. Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver. Viruses. 16(11): 1743, 2024.
?Nakahara H, Ono A, Hayes CN, Shirane Y, Miura R, Fujii Y, Murakami S, Yamaoka K, Bao H, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Oka S; Hiroshima Liver Study Group; TransSCOT Consortium. Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model. JCO Clin Cancer Inform. 8: e2400108, 2024.
?Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Kishi T, Ohishi W, Sakamoto N, Arihiro K, Hayes CN, Oka S. Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. J Gastroenterol. 60(3): 328-339, 2025.
?Shirane, Y., Fujii, Y., Ono, A., Nakahara, H., Hayes, C.N., Miura, R., Murakami, S., Sakamoto, N., Uchikawa, S., Fujino, H., Nakahara, T., Murakami, E., Yamauchi, M., Miki, D., Kawaoka, T., Arihiro, K., Tsuge, M., and Oka, S., Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma. Cancers, 2024. 16(7).
?Duehren, S., Uchida, T., Tsuge, M., Hiraga, N., Uprichard, S.L., Etzion, O., Glenn, J., Koh, C., Heller, T., Cotler, S.J., Oka, S., Chayama, K., and Dahari, H., Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice. Virus Res 349: p. 199451, 2024.
?Hiyama, Y., Fujino, H., Namba, M., Fujii, Y., Uchikawa, S., Ono, A., Nakahara, T., Murakami, E., Kawaoka, T., Miki, D., Tsuge, M., and Oka, S., Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs. Hepatology Research, 2024.
?Yamauchi M, Ono A, Amioka K, Fujii Y, Nakahara H, Teraoka Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Okamoto W, Miki D, Kawaoka T, Tsuge M, Imamura M, Hayes CN, Ohishi W, Kishi T, Kimura M, Suzuki N, Arihiro K, Aikata H, Chayama K, Oka S. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma. Commun Med (Lond) 3(1): 152, 2023.
?Hailegiorgis A, Ishida Y, Collier N, Imamura M, Shi Z, Reinharz V, Tsuge M, Barash D, Hiraga N, Yokomichi H, Tateno C, Ozik J, Uprichard SL, Chayama K, Dahari H. Modeling suggests that virion production cycles within individual cells is key to understanding acute hepatitis B virus infection kinetics. PLoS Comput Biol 19(8): e1011309, 2023.
?Suehiro Y, Tsuge M, Kurihara M, Uchida T, Fujino H, Ono A, Yamauchi M, Naswa Makokha G, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Aikata H, Nelson Hayes C, Fujita T and Chayama K. Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL. J Infect Dis 227: 686-695, 2023.
?Murakami S, Imamura M, Uchida T, Suehiro Y, Namba M, Fujii Y, Uchikawa S, Teraoka Y, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Kawaoka T, Miki D, Hayes NC, Tsuge M, Aikata H, Ohira M, Ohdan H and Oka S. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure. Hepatol Int 17: 1225-1232, 2023.
?Gad SA, Sugiyama M, Tsuge M, Wakae K, Fukano K, Oshima M, Sureau C, Watanabe N, Kato T, Murayama A, Li Y, Shoji I, Shimotohno K, Chayama K, Muramatsu M, Wakita T, Nozaki T and Aly HH. The kinesin KIF4 mediates HBV/HDV entry through the regulation of surface NTCP localization and can be targeted by RXR agonists in vitro. PLoS Pathog 18: e1009983, 2022.
?Tsuge M. Are humanized mouse models useful for basic research of hepatocarcinogenesis through chronic hepatitis B virus infection? Viruses, 13: 1920, 2021.
?Tsuge M. The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection. Liver Int, 41(12): 2836-2848, 2021.
【教育内容】
ウイルス性肝疾患における抗ウイルス疗法、肝臓癌における治疗选択、胃?食道静脉瘤に対する内视镜治疗、急性?慢性肝不全症例の治疗および肝移植に向けた全身管理など様々な肝疾患诊疗を行っている。特に、抗ウイルス疗法効果不良例への対応や肝臓癌の化学疗法、移植前の肝不全症例の管理は専门性が高く、他诊疗科や多职种との连携が不可欠であるため、肝臓専门医としての幅広い知识と技术を习得することができる。
【研究内容】
肝疾患に関する様々な基础?临床研究に取り组んでおります。
1．颁型慢性肝疾患に対する抗ウイルス疗法の治疗成绩と治疗后の発癌や线维化进展に関する临床研究
2．叠型肝炎ウイルスの感染?复製のメカニズムおよび発癌メカニズムに関する基础?临床研究
3．肝炎ウイルス感染や肝発癌と遗伝子多型との関连解析
4．肝疾患症例における肠内细菌丛の変化に関する基础研究
5．肝细胞癌に対する治疗成绩に関与する因子の基础?临床研究
Home
